Improved Survival and Response With Lenvatinib ± Everolimus vs Everolimus Alone in Metastatic RCC

May 29-June 2, 2015; Chicago, Illinois
Phase II results indicate promising efficacy of second-line treatment with lenvatinib alone or in combination with everolimus in mRCC.
Format: Microsoft PowerPoint (.ppt)
File Size: 540 KB
Released: June 4, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals, Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

In this commentary from Clinical Care Options (CCO), Alexander Drilon, MD, discusses best practices in the use of TRK inhibitor therapy

person default Alexander Drilon, MD Released: July 10, 2020

In this slideset from Clinical Care Options, Scot Niglio, MD provides insights on the latest data on immunotherapy approaches for bladder cancer, RCC, and prostate cancer.

Scot Niglio, MD Released: July 9, 2020

Gain key clinical insights fast, with this short slideset from CCO on the optimal use of immune checkpoint inhibitors for RCC

M. Dror Michaelson, MD, PhD Robert Motzer, MD Released: July 7, 2020

Gain key clinical insights fast, with this short slideset from CCO on treatment options for patients with urothelial cancer

Daniel P. Petrylak, MD
Program Director
Matthew I. Milowsky, MD Jonathan E. Rosenberg, MD
Released: July 7, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?